Company intelligence / Profile preview

Cerephex

Troy, Michigan, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

A randomized, sham-controlled clinical trial in 77 fibromyalgia patients demonstrated efficacy and safety of the proprietary treatment. Follow-up data presented at a major rheumatology meeting showed continued symptom relief at an average of 45 months post-treatment in a significant percentage of patients, with reduced use of pain medications and fewer office visits. The company is seeking regulatory clearance to commercialize its NeuroPoint device.

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Innovative Design Solutions (IDS) – partner for design, engineering & manufacturing.

Beyond the preview

Go deeper on Cerephex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerephex.

Explore the full profile